摘要
肝癌的治疗目前采用手术为主的综合治疗,但是由于原发性肝癌起病隐匿,多数患者在临床诊断时已失去了手术治疗的机会,即使是手术切除后也容易复发,缺乏有效的治疗药物和手段,总的治疗效果并不理想。生物治疗作为继手术、放疗、化疗后肿瘤治疗的第四种模式,已显示了良好的应用前景。
At present,surgery-based comprehensive therapy plays a dominant role in the treatment of hepatocellular carcinma( HCC). However,the majority of patients had no opportunity to undergo surgical treatment when diagnosis was confirmed. Furthermore,there is a high risk of tumor recurrence for patients with HCC even after surgical resection. The overall curative effect of HCC is far from satisfaction. Cancer biotherapy has now truly matured into the fourth modality of cancer treatmnet and proved to be useful in conjunction with surgery,chemotherapy and radiotherapy. The purpose of this article is to review the current status and progress of cellular immunotherapy for HCC
出处
《外科研究与新技术》
2013年第4期262-266,共5页
Surgical Research and New Technique
基金
国家十二五科技重大专项课题资助项目(2012ZX10002016-023)
国家自然科学基金资助项目(81372243)
关键词
肝癌
细胞免疫治疗
进展
Hepatocellular carcinoma
Cellular immunotherapy
Progress
